Alnylam and Ribopharma Merge; New Entity Secures $24.6M Financing | GenomeWeb

NEW YORK, July 7 - RNA interference firms Alnylam and Ribopharma today said they have merged and that the combined entity has raised an additional round of  € 21.5 million ($24.6 million) in private equity financing.


Get the full story

This story is free
for registered users

Registering provides access to this and other free content.

Register now.

Already have an account?
Login Now.

An opinion piece in the New York Times urges lawmakers to keep genetic protections in place.

Research funding in Canada is to remain mostly the same, ScienceInsider reports.

In Science this week: random DNA replication errors play role in cancer, and more.

The Bill and Melinda Gates Foundation embarks on an open-access publishing path.